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ABSTRACT 
 
Effects of Postmenopausal Hormone Replacement Therapy 
(HRT) And Early Age at Menopause on Endothelial Function 
among Korean Living in Rural Area 
Yunsu Choi 
Graduate School of Public Health 
Yonsei University 
 
Directed by Professor Sun Ha Jee, Ph.D. 
 
Introduction: The second leading cause of death in Korea is cardiovascular 
disease. Women’ menopause is known as a risk factor of cardiovascular disease, 
and endothelial dysfunction is an independent risk factor for coronary artery disease. 
Postmenopausal hormone replace therapy has many side effects and benefits, but 
there is still much controversy about cardiovascular disease. 
 
Objectives: We investigate the effect of postmenopausal period and hormone 
replacement therapy on endothelial function after adjusted coronary risk scores, 
marital status, abdominal obesity, and Obstetrics & Gynecological history. 
vi 
 
 
 
 
 
Methods: A total of 251 women who underwent the FMD test and had no missing 
variables were analyzed for the Health and Aging Cohort (HAC_YangPyeong). In 
the final regression analysis, a reweighting method was used for outliers. 
 
Results: Endothelial function was 1.75%p (p=0.04) lower in 51(20.3) women who 
had HRT and 51(20.3) women who experienced early menopause had 3.92%p 
(p=0.0002) lower. The short-term HRT usage were 2.07%p (p=0.054) lower and 
the long-term HRT usage were 1.31%p (p=0.285) lower than non-user. Decreased 
endothelial function when abdominal obesity defined were as WHR (p=0.012), 
long-term gynecological age (p=0.0006), high of KRS (p=0.005), and long 
postmenopausal period (p=0.059). In contrast, women who live alone was 
significantly higher than women who live together after the marriage (p=0.012). 
 
Conclusion: At the onset of HRT, the current age and the type of menopause as 
well as the coronary risk scores and duration of age at menarche to age at 
menopause should be considered. 
 
Keywords: Hormone replacement therapy (HRT), menopause, cardiovascular 
disease, endothelial function (FMD), early menopause, gynecological age 
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Ⅰ. INTRODUCTION 
 
1. Background 
 
Korea reached an aging society at 2000, also the elderly population is over 13% 
of the total population and entered the aged society. The death rate from heart 
disease was 55.6 deaths per 100,000 populations, 56.2 deaths per 100,000 of Korean 
women were found to be caused by heart disease. The second of common causes of 
death in Korea. The death from circulatory disease averaged 2.6%p increase over 
the previous year, also women were 13.8%p higher than men (KOSIS, 2017). The 
prevalence was higher in postmenopausal women (PMW) than men of the same age 
in chronic lifestyle-related diseases that require management such as obesity, total 
cholesterol, blood pressure and stroke according to Korea National Health & 
Examination Survey (KNHNES) in 2016.  
Multiple previous studies suggested menopause is a risk factor for 
cardiovascular disease and cause of the decrease in endothelial function (Colditz et 
al., 1987; He et al., 2012). The cause of increased circulatory disease in PMW is 
the loss of estrogenic cardioprotective function and exposure to various risk factors 
(Colacurci et al., 2003; Gray et al., 2001; Grodstein and Stampfer, 1998; Sader and 
- 2 - 
 
 
 
 
 
Celermajer, 2002). The vascular endothelial function is the difference between 
vasodilatation and stabilization by nitric oxygen (NO). The NO in the body 
decreases gradually as aging, and the endothelial function also decreases (Raitakari 
and Celermajer, 2000). Decreasing endothelial function is an important independent 
indicator of the early abnormalities of cardiovascular and is associated with 
atherosclerosis and cardiovascular disease occurrence (Fathi et al., 2004; Synn, Bae 
and Kim, 2004). Coronary heart disease (CHD) would be directly or indirectly 
association with severe vascular related diseases such as heart or kidney failure, and 
ischemic stroke, cerebral infarction, cerebral hemorrhage. 
In Japan, the hormonal changes according to the menstrual cycle had a 
significant association with the endothelial function test (Flow-mediated dilatation, 
FMD). The Blood flow was higher in the luteal phase and the follicular phase just 
before ovulation than in the menstrual period (Hashimoto et al., 1995). The results 
suggest that hormone exposure through the female menstrual cycle has a protective 
effect on cardiovascular disease. Another study, in Italy, that considered time since 
menopause suggested endothelial function was relatively higher in women who had 
early HRT after menopause and was more relevant than the change due to aging 
(Vitale et al., 2008).  
The postmenopausal hormone replacement therapy (HRT) is used to relieve 
menopause symptoms such as hot flashes, night sweats, sleep disorder, vaginal 
dryness and weight gain with a slow metabolism (Barrett-Connor, 1998; Manson 
and Martin, 2001). HRT consists of patches, injections, oral pills, and has been 
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reported to vary in effectiveness depending on the combination of regimens. A 
single long-term use of estrogen has a preventive effect on osteoporosis. It also 
reduces the risk of CHD and affects the survival rate of women, while increasing 
the risk of endometrial cancer, stroke, and fracture, the risk of breast cancer during 
treatment (Barrett-Connor, 1998; Manson and Martin, 2001). Because of these 
prevention or risk effects of HRT, it is necessary to consider the timing of treatment, 
the type of preparations, the period of usage, in addition, diseases history of the 
patient and their family. 
Postmenopausal women’s HRT may be used for prevention of cardiovascular 
diseases, but the cardio-protective effect was decreased as the aging progressed 
after HRT. In some studies, there was no cardio-protective effect of when the 
women who has many years since menopause (Vitale et al., 2008) or older who 
experienced any kind of menopause, probably due to an estrogen receptor that could 
not overcome the effects of aging on endothelial function and predicted that was 
would be related genetic methylation (Herrington et al., 2001; Kalantaridou et al., 
2006). 
Women affected not only menopausal hormone changes but also the risk of 
cardiovascular disease due to periodic hormone exposure by the menstrual cycle. 
Exposure of hormones does not only affect women’s menstrual characteristics but 
also is closely related to the history of obstetrics and gynecology such as the 
frequency of deliveries, age at first pregnancy, breast-feeding and oral 
contraceptive pill use, etc.  
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However, they could not consider about CHD risk. The studies of coronary 
artery disease have been ongoing, and many studies have identified risk factors. 
Based on these risk factors, the Framingham risk scores (FRS) equation for 
Caucasian was developed in the Framingham Heart Study (Wilson et al., 1998). 
The calculation method is the coronary artery disease risk scores using categorized 
such as blood pressure, total cholesterol, HDL and LDL. There is a difference in 
the risk of racial cardiovascular disease because the equation does not consider it. 
The commonly used Framingham risk scores (FRS) tends to be overestimated for 
coronary heart disease (CHD) predictions when applied to Koreans (Jee et al., 2014). 
The coronary risk scores for Korean (KRS) has ranges from 0 to 1, and the closer 
to 1 that higher the risk of CHD. Therefore, the effect of hormone therapy should 
be confirmed by using the risk scores of coronary heart disease developed for 
Koreans. 
The aim of this study is to investigate the relationship between HRT and time 
of age at menopause with endothelial-dependent function adjusted KRS and to 
confirm association with endothelial-dependent vasodilation function and the HRT 
for prevention of cardiovascular disease among Korea rural area Postmenopausal 
women. 
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2. Objectives 
 
In this study, we selected subjects who completed all the tests for calculating 
coronary risk scores among postmenopausal women (PMW) who participated in an 
FMD test in 2011 and 2013.  
 
The specific aim of the study is as follows. 
1. To confirm the relationship between the HRT at postmenopausal and 
difference in endothelium-dependent function measured by FMD in Korean rural area. 
 
2. To determine the relationship between the endothelium-dependent 
function by the time of menopause (early menopause, normal or late menopause) and 
coronary risk scores for Korean (KRS). 
 
 
3. To confirm the correlation between social factors, health behaviors, history 
of disease and OB/GY history affecting the duration of hormone exposure that was 
related to the risk of endothelium-dependent function. 
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Ⅱ. MATERIALS AND METHODS 
 
1. Study Design 
 
Figure 1. The frame of study 
 
This study was to investigate the effect of HRT among PMW and Time of age 
at menopause on endothelial function. The vascular endothelial function is assessed 
by the change rate measured as a Flow-mediate dilatation (FMD) test.  
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The confounding variables include age, sociological factors, the coronary risk 
scores for Korean (KRS), anthropometric measurements, menstrual characteristics 
and Obstetrics & Gynecological history. 
 
2. Study Participants  
 
The Health and Aging Cohort_YangPyeong (HAC_YangPyeong) data, which 
was designed prospective cohort study to research the prevalence and risk factors 
developing assessment tools for health, disease, and disability among the elderly in 
the rural community. At the time of the analysis, this study was used as cross-
sectional considered repeated data within the prospective data.  
The study target population were women who experienced menopause and got 
a FMD result living in rural areas (Yangpyeong, Gyeonggi, Republic of Korea). For 
the calculation of Korean CHD risk scores (KRS), the participants who have missed 
one of the variables that blood pressure, High-density lipoprotein (HDL), Total 
cholesterol, smoking status and diabetes history were excluded from the analysis. 
In addition, by confirming the association with females, the participants who 
answered all the answers of the obstetrics & gynecological history were selected. 
Among 3,565 individuals, 2,196 of the women (61.6%) who underwent the FMD 
test in 2011 or 2013 for baseline or repeat survey, thus 251 adults (mean age; 62.2) 
included who had no missing in the main questionnaire were selected (Figure 2). 
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Figure 2. Exclusion criteria for research participants 
Number of Total 
n=3,565 
Women who got a FMD test score 
n=378 
Women who experienced 
menopause 
n=288 
251 individuals were 
Included for analysis 
Excluded (n=27)  
     * Missing of HRT (n=4) 
     * Missing of Breast feeding experience (n=5) 
     * Missing of Frequency of delivery (n=1) 
     * Missing of Body Mass Index (BMI) (n=17) 
Women who underwent physical 
measurement and clinical 
examination 
 
Excluded (n=90)  
     * Who has no experience of menopause (n=51) 
     * Missing of Age at Menopause (n=18) 
     * Missing of type of Menopause (n=16) 
     * Missing of Age at Menarche (n=5) 
Excluded (n=3,187)  
     * Men (n=1,369) 
     * Missing of FMD (n=1,818) 
Excluded (n=5)  
     * Missing of Marriage status (n=1) 
     * Missing of Education level (n=1) 
     * Missing of Physical activity (n=3) 
Women who answered for 
sociological status and health 
behavior 
 
Excluded (n=5)  
     * Missing of Diagnosis of CVD (n=3) 
     * Missing of Duration of HRT dosage (n=2) 
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3. Data Collection 
 
3.1. Survey Questionnaire 
Questions that are not likely to change about experienced once in a lifetime, 
such as “At what age did you have menarche?” was open-ended and asked at the 
time of the baseline survey. However, questions that could be changed consistently 
such as “Have you ever been diagnosed with a new disease from a doctor since your 
last survey?” were reviewed for changes at the last repeated surveys.   
 
3.2. Blood Test Results and Anthropometry Variables 
Blood tests which once in each investigation are performed on fasting status. 
All individuals have undergone tests at repeated survey after the baseline survey, 
and only once of the twice results were diagnosed if they were included in the 
reference range. Hemoglobin is relatively likely to change using the results at the 
time of FMD test. 
The changeable anthropometry variable such as height, weight, waist 
circumference, and hip circumference in the elderly used the results at the time of 
FMD test. In the case of blood pressure, which can be changed according to 
condition, time and place at the time of measurement, based on twice in each 
investigation. The average value of each investigation was calculated and diagnosed 
when the average value was included in the reference range more than once. 
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3.3. Measurement of Endothelial Function 
Endothelial function was assessed by measuring endothelium-dependent 
vasodilation using Pulsed Doppler. The vasodilation is calculated by the diameter 
varying with the degree of vasodilation. After sufficient rest, the baseline diameter 
in ballast condition is measured. The upper arm is wrapped with a compression pad, 
the compression band is inflated with a pressure of 250 mmHg for 5 minutes to 
block blood flow to the upper arm, and the increased blood flow and the diameter 
of the maximum in the brachial artery are measured while relaxing the compression 
arm. The FMD was calculated by the percentage of the difference between the 
diameter of baseline and the diameter of the maximum is divided by the baseline 
diameter (Corretti et al., 2002; Thijssen et al., 2011). 
 
3.4. Hormone Replacement Therapy (HRT) 
“Have you taken hormone medication for postmenopausal treatment?”. The 
former and the current users were defined as those who experienced HRT and 
included in the analysis only for those who clearly answered the duration of HRT 
usage. The subjects who did not receive HRT defined of the duration of HRT usage 
as 0 month and included in the analysis.  
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3.5. Operational Definition of Variables (Table 1) 
Age is redefined as the age at which the FMD test was performed. The Korean 
CHD risk scores (KRS) were used to predict the risk of CHD. The KRS is a 
coronary risk score equation for Koreans considering gender, age, hypertension, 
HDL, total cholesterol, smoking status and diabetes (Jee et al., 2014). 
Hypertension is measured twice in each investigation, it is defined that the 
average is calculated for each cycle of investigation, in addition, blood sampling 
such as total cholesterol, HDL and FBS are performed once in a single investigation. 
The diagnosis was defined as when at least once in the baseline or repeated survey 
is included in the reference range. 
About the reason for menopause, except for natural menopause, menopause 
due to drugs, uterus or ovary excision was classified as surgical menopause. 
Menopause was divided into early menopause (under 45 years), normal menopause 
(46-55 years) and delayed menopause (over 56 years), while Menarche was divided 
normal menarche (under 16 years) and delayed menarche (over 17 years). 
Gynecological age was defined as the duration between age at menarche and age at 
menopause. Age at first pregnancy was defined as the age of 30 years or older, 
considering that the participants are elderly persons. 
Body mass index (BMI) was calculated as weight (kg) / height 2 (m) that are 
measured at the time of the FMD test. BMI is defined that used WHO standard BMI 
cutoff as normal or underweight (less than 23 kg/m2), overweight (less than 25 
kg/m2), obesity (equal or over 25 kg/m2). Abdominal circumference is defined as 
- 12 - 
 
 
 
 
 
abdominal obesity when the female standard exceeds 85cm (Lee et al., 2006). The 
WHR (Waist-Hip Ratio) is calculated as the ratio of waist to hip measured at the 
time of FMD test and is classified as a risk group when it exceeds 0.86. Hemoglobin 
levels are measured at the time of FMD test and defined as anemia if is less than 12 
g/dL. 
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Table 1. Operational definition of variables 
 
Variable Operational Definition
Age Age at got a FMD test (as of 2011 or 2013)
FMD (%)
* Higher is better, Endothelial dysfunction; ≤8
Coronary Risk Scores The Korean CHD Risk Scores (KRS) for women (Jee et al. 2014)
Blood pressure (mmHg)
JNCⅦ Criteria
Normal: SBP<120 , DBP<80
Pre-HTN: 120≤SBP<140, 80≤DBP<90
Stage 1 HTN: 140≤SBP, 90≤DBP<100
Stage 2 HTN: 160≤SBP, 100≤DBP
Total cholesterol (mg/dL) <160, 160≤ TC <200, 200≤ TC <240, 240≤ TC <280, 280≤
High Density Lipoprotein (mg/dL) <35, 35≤ HDL <45, 45≤ HDL <50, 50≤ HDL <60, 60≤
Fasting Blood Glucose (mg/dL) Normal: <126 mg/dLDiabetes mellitus: ≥126 mg/dL
Type of menopause Natural menopause: menopause due to agingSurgical menopause: menopause due to drugs, uterus or ovary excision
Age at menopause
Early menopause: ≤45 years
Normal menopause: 46-55 years
Delayed menopause: ≥56 years
Age at menarche Normal menarche: ≤16 yearsDelayed menarche: ≥17 years
Gynecological age Duration between menarche with menopause(= Age at menopause - Age at menarche)
Age at first pregnancy Pregnancy of young maternal age: <20 yearspregnancy of advanced maternal age: ≥30 years
Body Mass Index (kg/m2)
BMI = weight (kg) / height2 (m)
WHO Asia Pacific criteria
Normal or less : <23 kg/m2 , Overweight: <25  kg/m2 , Obesity:  ≥25  kg/m2
Abdominal obesity Abdominal circumference ≥ 85 cm (Lee et al. 2006)
Waist-Hip Ratio (WHR)
Hemoglobin (g/dL) Anemia: <12Normal: ≥12
(Maximun Diameter − Baseline Diameter)Baseline Diameter  × 100
Waist circumferenceHip circumferece
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4. Statistical Analysis 
 
All variables requiring mathematical computations such as KRS, BMI, WHR, 
and gynecological age used statistical programs. The general linear model (GLM) 
procedure was used for the variance comparison and the LSMEANS option was 
used for the age-adjusted mean. To classify the age effects, both of crude and age-
adjusted model probabilities are presented. The final model analysis was a linear 
regression analysis as a continuous variable using REG procedure. The variable of 
multiple models was excluded when VIF >10. For the optimal regression equation, 
the stepwise method of multivariable selection of the REG procedure was used. The 
significance level for entry (SLE) into regression model is defined 0.15. The final 
regression equation was dealt outliers and influences defined as when the student 
residuals do not include -2 to 2. The subjects who are classified into outliers and 
influences used the REWEIGHT statement of REG procedure rather than the 
exclusion or imputation method. The reweighted value was defined as 0.8 (when 
the residual absolute value was between 2 to 3), 0.6 (between 3 to 5), 0.4(between 
5 to 7), and 0.05 (over 7). The covariates were selected for a final model consider 
the effect modification (interaction) between covariate. P-value <0.05 were 
considered statistically significant. We used statistical program, SAS Enterprise 
Guide version 9.4 (SAS Institute Inc., North Carolina, USA) to analyze. 
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Ⅲ. RESULTS 
 
1. General characteristics 
 
The 251 women aged 45 to 88 years who underwent FMD and experienced 
menopause in the Yangpyeong area’s mean age was 62.2 years (mean ± SE, 62.2 ± 
0.52). The 207(82.5%) women were married or living together, and about 
233(92.8%) had an education level below high school graduation. The mean of the 
FMD test was 6.9% and 161(64.1%) had vascular endothelial dysfunction. The 
43(17.2%) of women were diagnosed with CVD such as hypertension and 
myocardial infarction. Blood pressure, total cholesterol, HDL, smoking status and 
diagnosis of diabetes mellitus were categorized for KRS (0.01 ± 0.009). Except for 
the pre-hypertension group, the 63(25.1%) were hypertensive and the 48(19.1%) 
had HDL less than 45 mg/dL. Also, 30(11.9%) had a diagnosis of diabetes or more 
than 126 mg/dL at FBS test. In a survey of health behavior, the 91(36.3%) had 
experience of lifelong drinking. The 215(85.7%) of the participants experienced 
natural menopause. The 176(70.1%) experienced normal menarche, and 200(79.7%) 
experienced normal or late menopause. A mean of gynecological age were 33 years, 
and 148(59.0%) had more than mean gynecological age. The 57(22.7%) had 
undergone menopause within 5 years. Experience with lifetime hormone 
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replacement therapy (HRT), including past and current, was 51(20.3%) in all, and 
59(23.5%) of patients who took oral contraceptives. Only 10(4.0%) of subjects was 
pregnant at an old age. The 168(66.9%) were overweight or over, and 197(78.5%) 
had abdominal obesity. The 19(7.6%) women had anemia. (Table 2) 
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Table 2. General characteristics of participants 
 
  
62.2 ± 0.52 Type of Menopause
45-49 12(4.8) Natural menopause 215(85.7)
50-59 99(39.4) Surgical menopause 36(14.3)
60-69 95(37.9) Age at Menarche (yr) * 15.5 ± 0.12
70-88 45(17.9) Normal menarche (≤16) 176(70.1)
Marrital status Delayed menarche (≥17) 75(29.9)
Marriage / Living together 207(82.5) Age at menopause (yr) * 48.4 ± 0.31
Seperation / Divorce / Bereavement 44(17.5) Early menopause (≤45) 51(20.3)
Education level Normal menopause (46-55) 191(76.1)
Middle school or less 120(47.8) Late menopause (≥56) 9(3.6)
High school or less 113(45.0) Gynecological age (yr) * 33.0 ± 0.32
College or less 10(4.0) <33 103(41.0)
Graduate school or more 8(3.2) ≥33 148(59.0)
Flow mediated dilatation (FMD, %) * 6.9 ± 0.43 Years since menopause (yr) * 13.7 ± 0.60
Endothelial dysfunction (≤8.0) 161(64.1) ≤5 57(22.7)
Normal (>8.0) 90(35.9) >5 194(77.3)
Diagnosis of CVD  † Hormone replacement teraphy (HRT)
Before menopause 10(4.0) None use 200(79.7)
After menopause 33(13.2) User (Past/Current) 51(20.3)
Korean CHD risk scores (KRS) * 0.01 ± 0.009 Duration of HRT usage (months)
≤0.01280 169(67.3) ≤12 29(11.5)
≤0.13330 ‡ 82(32.7) >12 22(8.8)
Hypertension (JNCⅦ) Take an oral contraceptive pill
None 72(28.7) None use 192(76.5)
Pre-hypertension 116(42.2) User (Past/Current) 59(23.5)
Stage 1 hypertension 46(18.3) Age at first pregnant * 23.7 ± 0.22
Stage 2 hypertension 17(6.8) <20 24(9.5)
Total cholesterol (mg/dL) 20-30 217(86.5)
<160 12(4.8) >30 10(4.0)
160-199 81(32.3) Frequency of deliveries * 3.1 ± 0.09
200-239 108(43.0) ≤3 171(68.1)
240-279 41(16.3) >3 80(31.9)
≥280 9(3.6) Breast feeding
High density lipoprotein (mg/dL) No 16(6.4)
<35 6(2.4) Yes 235(93.6)
35-44 42(16.7) Body Mass Index (kg/m2) * 24.9 ± 0.21
45-49 41(16.3) Normal weight or less (<23.0) 83(33.1)
50-59 89(35.5) Over weight (<25.0) 58(23.1)
≥60 73(29.1) Obesity (≥25.0) 110(43.8)
Smoking Abdominal circumference (cm) * 86.4 ± 0.52
Non-smoker 247(98.4) ≤85 106(42.2)
Ever smoker 4(1.6) >85 (Abdominal obesity) 145(57.8)
Diabetes mellitus Waist - Hip ratio (WHR) * 0.9 ± 0.004
No 221(88.1) ≤0.86 54(21.5)
Yes 30(11.9) >0.86 (Abdominal obesity) 197(78.5)
Alcohol intake Hemoglobin (g/dL) * 13.2 ± 0.06
Non-drinker 160(63.8) <12 (Anemia) 19(7.6)
Drinker (including past drinker) 91(36.3) ≥12 232(92.4)
* Mean ± SE  † Cardiovascular disease such as hypertension, myocardial infarction, and angina pectoris ‡ Tertile 3 (≥67%)
Variable N (%)(n=251)Variable
Age (yr) *
N (%)
(n=251)
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2. The association between key variables 
 
2.1. Relevance according to FMD levels 
FMD levels were classified as a normal group (> 8) and endothelial 
dysfunction group (≤ 8). There was no difference in the mean between Korean 
coronary risk scores. (Figure 3) 
 
 
Figure 3. The Korean coronary risk scores for women by FMD levels 
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The difference in FMD levels with age at menarche, age at menopause and 
gynecological age was the normal group’s time of menarche and menopause was 
later than endothelial dysfunction group. However, the gynecological age was 
slightly shorter. The difference between the groups was not significant. (Figure 4) 
 
 
Figure 4. Menstrual characteristics by FMD levels. 
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2.2. Relevance according to time of age at menopause 
Korean coronary risk scores differ according to the time of age at menopause, 
and there was a significant difference between early or normal menopause with 
delayed menopause. (Figure 5)  
 
Figure 5. Korean coronary risk scores by time of age at menopause 
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Depending on the time of age at menopause, the endothelial function 
dropped immediately after the menopause and the FMD increased slowly with 
years since menopause, then decreased again. It showed different morphology 
between the group. (Figure 6) 
 
 
Figure 6. Difference in median of endothelial function with age by time of age at 
menopause 
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2.3. Relevance according to Hormone replacement therapy 
The endothelial function was significantly decreased in the menopausal period 
(45 to 50 years) in relation to age and endothelial function according to hormone 
therapy. There was a tendency for FMD to recover after age 55 in all groups, 
regardless of hormone therapy, and decreased again after age 60 years. The age-
related changes in all groups were similar, however, the differences between the 
groups according to hormone treatment were statistically significant. (Figure 7) 
 
 
  Figure 7. Difference in median of endothelial function with age by HRT usage 
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The difference of coronary risk scores according to hormone therapy was 
lowered in the hormone treated group than in the untreated group. This is 
statistically significant. (Figure 8) 
 
 
Figure 8. Korean coronary risk scores by HRT usage 
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3. The mean difference of endothelial function 
 
3.1. The endothelial function comparison with sociological status and 
health behavior 
The FMD tended to decrease with increasing age (crude p = 0.475). The FMD 
mean indicates women who are living alone had higher FMD than those who were 
married or living together, moreover, the difference existed in the age-adjusted 
mean (age adjusted p = 0.024). There was no difference according to the level of 
education, however, the age-adjusted mean was lower for college graduates or more 
(age adjusted p = 0.738). At the time of the diagnosis of CVD, diagnosis of CVD 
at before the menopause group had a higher mean of FMD rather than diagnosis at 
after the menopause or never diagnosed, however, there was no statistically 
significant difference (crude p = 0.136, age-adjusted p = 0.263). The FMD mean 
was not statistically significant in the components for KRS calculation (age, blood 
pressure, total cholesterol, HDL, smoking status, diabetes mellitus), however, the 
FMD was lower as the calculated KRS score increased (crude p = 0.044). Alcohol 
intake (crude p = 0.857, age-adjusted p = 0.555). (Table 3a) 
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Table 3a. The linear model analysis (GLM) for FMD with sociological status and health 
behavior 
 
FMD FMD
Mean  ± SE * Mean † ± SE
6.89 ± 0.43
45-49 7.90 ± 1.98
50-59 7.63 ± 0.69
60-69 6.34 ± 0.71
70-88 6.17 ± 1.02
Marrital status
Marriage / Living together 6.58 ± 0.48 6.41 ± 0.48
Seperation / Divorce / Bereavement 8.37 ± 1.03 9.15 ± 1.09
Education level
Middle school or less 6.85 ± 0.63 7.25 ± 0.67
High school or less 6.97 ± 0.65 6.67 ± 0.67
College or more 6.67 ± 1.63 5.94 ± 1.68
Diagnosis of CVD  ‡
None 7.18 ± 0.47 7.13 ± 0.48
Before menopause 8.07 ± 2.16 8.01 ± 2.17
After menopause 4.71 ± 1.19 5.03 ± 1.24
Korean CHD risk scores (KRS)
≤0.01280 7.50 ± 0.53
≤0.13330 § 5.64 ± 0.75
Hypertension (JNCⅦ)
None 7.40 ± 0.81 7.11 ± 0.84
Pre-hypertension 7.04 ± 0.64 7.13 ± 0.64
Stage 1 hypertension 5.69 ± 1.02 5.77 ± 1.02
Stage 2 hypertension 6.94 ± 1.67 7.41 ± 1.70
<160 7.44 ± 1.99 7.20 ± 1.99
160-199 7.69 ± 0.77 7.69 ± 0.76
200-239 6.45 ± 0.66 6.47 ± 0.66
240-279 6.84 ± 1.08 6.83 ± 1.07
≥280 4.42 ± 2.30 4.65 ± 2.30
High density lipoprotein (mg/dL)
<35 9.64 ± 2.80 9.78 ± 2.80
35-44 6.37 ± 1.06 6.41 ± 1.06
45-49 7.86 ± 1.07 7.86 ± 1.07
50-59 6.03 ± 0.73 6.03 ± 0.73
≥60 7.47 ± 0.80 7.44 ± 0.80
Smoking
Non-smoker 6.83 ± 0.44 6.82 ± 0.44
Ever smoker 10.97 ± 3.43 11.09 ± 3.42
Diabetes mellitus
No 6.83 ± 0.46 6.80 ± 0.46
Yes 7.38 ± 1.26 7.59 ± 1.26
Alcohol intake
Non-drinker 6.83 ± 0.54 6.90 ± 0.55
Drinker (including past drinker) 7.00 ± 0.72 6.87 ± 0.730.857 0.970
0.680
0.598 0.653
0.680 0.555
0.232 0.217
0.420 0.412
0.738
0.044 -
0.605
-
* Standard Error (SE)   † Age adjusted mean  ‡  Cardiovascular disease such as hypertension, myocardial infarction, and angina pectoris
§ Tertile 3 (≥67%)
0.136 0.263
Variable Crudep  value
Age adjusted
p  value
FMD (n=251)
-
Total cholesterol (mg/dL)
Age (yr)
0.475 -
0.117 0.024
0.982
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3.2. The endothelial function comparison with Obstetrics & gynecological 
characteristics and anthropometry 
The mean FMD of postmenopausal women according to their gynecological 
history and anthropometry was compared. The mean FMD in the women who 
experienced surgical menopause was lower than that compared with natural 
menopause, and the difference was similar after age-adjusted model (crude p = 
0.337, age-adjusted p = 0.261). The age-adjusted mean was 0.95%p higher in 
delayed menopause (over 17 years) compared with the normal menopause. There 
was no significant difference between the two groups (crude p = 0.486, age-adjusted 
p = 0.323). The years since menopause being less than 5 years, FMD was 2.7 higher 
(crude p = 0.009, age-adjusted p = 0.031) than more of 5 years group. Compared 
with the untreated, postmenopausal hormone replacement therapy was 2.3%p 
higher (p = 0.031), and 2.7%p higher after age-adjusted (p = 0.014). However, there 
was no difference of age-adjusted FMD mean according to lifetime oral 
contraceptive use (p = 0.329), and 1.3%p higher when the frequency of delivery 
was below 3 (p = 0.245). Also, age-adjusted FMD mean of breastfeeding were 1.0 
lower in the women who experienced breastfed (p = 0.575). The age-adjusted FMD 
mean compared to the first pregnancy age was 3.4%p lower in advanced maternal 
age group (≥30) than normal group (< 30 years) (age-adjusted p = 0.121).  
FMD was highest when body mass index (BMI) was normal, and lowest when 
overweight (age adjusted p = 0.426). In the case of abdominal obesity confirmed 
only by abdominal circumference, it was 0.6%p lower than normal group (age-
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adjusted p = 0.455). The WHR based on the ratio of abdominal and hip 
circumference was 2.8%p lower than the normal group (age-adjusted p = 0.011). 
The women who have anemia were 2.8%p lower than normal group (crude p = 
0.145, age-adjusted p = 0.090), however, there was no significant difference. (Table 
3b)  
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Table 3b. The Linear model analysis (GLM) for FMD with Obstetrics & gynecological 
characteristics and anthropometry 
 
FMD FMD
Mean  ± SE * Mean † ± SE
6.89 ± 0.43
Type of Menopause
Natural menopause 7.06 ±0.47 7.09 ±0.47
Surgical menopause 5.87 ±1.14 5.69 ±1.15
Age at Menarche (yr)
Normal menarche (≤16) 6.69 ±0.52 6.61 ±0.52
Delayed menarche (≥17) 7.36 ±0.79 7.56 ±0.80
Age at menopause (yr)
Early menopause (≤45) 4.33 ± 0.95 4.26 ± 0.94
Normal or late menopause (>46) 7.54 ± 0.48 7.56 ± 0.48
Gynecological age (yr)
<33 7.06 ± 0.68 7.18 ± 0.68
≥33 6.77 ± 0.57 6.69 ± 0.57
Years since menopause (yr)
≤5 8.97 ± 0.90 8.98 ± 1.05
>5 6.28 ± 0.49 6.28 ± 0.51
Hormone replacement teraphy (HRT)
None use 7.36 ± 0.48 7.43 ± 0.48
User (Past/Current) 5.03 ± 0.95 4.76 ± 0.96
Duration of HRT usage (months)
None use 7.36 ± 0.48 7.43 ± 0.48
≤12 5.81 ± 1.27 5.48 ± 1.27
>12 4.02 ± 1.45 3.82 ± 1.45
Take an oral contraceptive pill
None use 7.16 ± 0.50 7.13 ± 0.50
User (Past/Current) 6.03 ± 0.89 6.12 ± 0.89
Frequency of deliveries
≤3 7.41 ± 0.52 7.30 ± 0.56
>3 5.77 ± 0.76 6.02 ± 0.87
Breast feeding
No 6.92 ± 0.45 6.96 ± 0.45
Yes 6.40 ± 1.72 5.94 ± 1.74
Age at first pregnant
≤30 7.02 ± 0.44 7.03 ± 0.44
>30 3.68 ± 2.17 3.59 ± 2.16
Body Mass Index (kg/m2)
Normal weight or less (<23.0) 7.40 ± 0.75 7.48 ± 0.75
Over weight (<25.0) 5.93 ± 0.90 5.95 ± 0.90
Obesity (≥25.0) 7.01 ± 0.66 6.94 ± 0.66
Abdominal circumference (cm)
Normal 7.36 ± 0.67 7.27 ± 0.67
Abdominal obesity 6.55 ± 0.57 6.61 ± 0.57
Waist - Hip ratio (WHR)
Normal 9.24 ± 0.92 9.07 ± 0.96
Abdominal obesity 6.25 ± 0.48 6.29 ± 0.49
Hemoglobin (g/dL)
Normal 9.10 ± 1.57 9.48 ± 1.58
Anemia 6.71 ± 0.45 6.68 ± 0.45
* Standard Error (SE)   † Age adjusted mean
0.353
0.004
0.446
0.323
0.003 0.002
0.740
0.009
0.031
0.273
0.078
0.145
0.588
0.031
0.014
0.329
0.245
0.575
0.455
0.011
0.090
0.131 0.121
0.770
0.426
0.063 0.034
0.337 0.261
0.486
Variable Crudep  value
Age adjusted
p  value
FMD (n=251)
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4. The frequency analysis according to HRT usage 
 
4.1. The HRT usage comparison with sociological status and health 
behavior 
The elderly group mostly did not receive hormone treatment and the 
distribution was similar in all age group (crude p = 0.002). There was no difference 
of frequency in marital status (crude p = 0.426, age-adjusted p = 0.846) and 
education levels (crude p = 0.570, age-adjusted p = 0.877). Most of the diagnosis 
of CVD before the menopause women did not receive HRT, and there was no 
difference in HRT along with diagnosis of CVD after the menopause (crude p = 
0.711, age-adjusted p = 0.407). The KRS was higher in untreated group (crude p = 
0.059), per contra no significant correlation in KRS components such as blood 
pressure (crude p = 0.343, age adjusted p = 0.631), total cholesterol (crude p = 0.659, 
age adjusted p = 0.666), HDL (crude p = 0.571, age adjusted p = 0.608), smoking 
status (crude p = 0.815, age adjusted p = 0.762) and diabetes mellitus (crude p = 
0.313, age adjusted p = 0.484). Lifetime drinking experience was higher in the 
untreated group (crude p = 0.144, age adjusted p = 0.055). (Table 4a) 
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Table 4a. The HRT usage comparison with sociological status and health behavior 
 
HRT Non-user HRT User
N 200(79.7) 51(20.3)
7.43 ± 0.48 4.76 ± 0.96 - 0.014
45-49 6(3.0) 6(11.8)
50-59 79(39.5) 20(39.2)
60-69 72(36.0) 23(45.1)
70-88 43(21.5) 2(3.9)
Marrital status
Marriage / Living together 163(81.5) 44(86.3)
Seperation / Divorce / Bereavement 37(18.5) 7(13.7)
Education level
Middle school or less 99(49.5) 21(41.2)
High school or less 87(43.5) 26(51.0)
College or more 14(7.0) 4(7.8)
Diagnosis of CVD  †
None 165(82.5) 43(84.3)
Before menopause 9(4.5) 1(2.0)
After menopause 26(13.0) 7(13.7)
Korean CHD risk scores (KRS)
≤0.01280 129(64.5) 40(78.4)
≤0.13330 ‡ 71(35.5) 11(21.6)
Hypertension (JNCⅦ)
None 54(27.0) 18(35.3)
Pre-hypertension 91(45.5) 25(49.0)
Stage 1 hypertension 40(20.0) 6(11.8)
Stage 2 hypertension 15(7.5) 2(3.9)
<160 8(4.0) 4(7.8)
160-199 65(32.5) 16(31.4)
200-239 88(44.0) 20(39.2)
240-279 33(16.5) 8(15.7)
≥280 6(3.0) 3(5.9)
High density lipoprotein (mg/dL)
<35 6(3.0) 0(0.0)
35-44 35(17.5) 7(13.7)
45-49 30(15.0) 11(21.6)
50-59 71(35.2) 18(35.3)
≥60 58(29.0) 15(29.4)
Smoking
Non-smoker 197(98.5) 50(98.0)
Ever smoker 3(1.5) 1(2.0)
Diabetes mellitus
No 174(87.0) 47(92.2)
Yes 26(13.0) 4(7.8)
Alcohol intake
Non-drinker 123(61.5) 37(72.6)
Drinker (including past drinker) 77(38.5) 14(27.5)
* Age adjusted mean ± SE  † Cardiovascular diseases such as hypertension, myocardial infarction, and angina pectoris ‡ Tertile 3 (≥67%)
0.144 0.055
0.571 0.608
0.815 0.762
0.313 0.484
0.059 -
0.711 0.407
0.570 0.877
0.659 0.666
Total cholesterol (mg/dL)
0.343 0.631
Variable
N (%) Crude
p  value
Age adjusted
p  value
FMD *
Age (yr)
0.002 -
0.426 0.846
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4.2.The HRT usage comparison with obstetrics & gynecological 
characteristics and anthropometry 
The 17(33.3%) women of those who received HRT were experienced surgical 
menopause, and most of the women who experienced menopause due to aging did 
not receive HRT (crude p <0.0001, age-adjusted p <0.0001). Women who 
experienced normal age at menarche (crude p = 0.148, age-adjusted p = 0.334) or 
normal or late age at menopause (crude p = 0.306, age-adjusted p = 0.366) were 
more likely to receive HRT, no one received HRT who experienced delayed 
menopause (46 years or more). There was no difference in frequency of HRT 
according to gynecological age (crude p = 0.734, age-adjusted p = 0.461) and years 
since menopause (crude p = 0.367, age-adjusted p = 0.430). The HRT usage was 
positively related to oral contraceptive pills (crude p = 0.064, age-adjusted p = 
0.034). Relatively who experienced deliveries less than 3 babies (crude p = 0.005, 
age-adjusted p = 0.116), and did not experienced breastfeed (crude p = 0.873, age-
adjusted p = 0.509) was more received HRT. There was no difference in HRT 
according to the first age at pregnancy (crude p = 0.440, age-adjusted p = 0.478). 
There was no association with hormone therapy according to BMI (crude p = 
0.677, age-adjusted p = 0.681). Women who has abnormal range of waist 
circumference (crude p = 0.273, age adjusted p = 0.451) and WHR (crude p = 0.021, 
age adjusted p = 0.112) more received HRT. There was no difference according to 
Hb (crude p = 0.934, age adjusted p = 0.622). (Table 4b) 
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Table 4b. The HRT usage comparison with Obstetrics & gynecological characteristics and 
anthropometry  
 
 
 
  
HRT Non-User HRT user
N 200(79.7) 51(20.3)
Type of Menopause
Natural menopause 181(90.5) 34(66.7)
Surgical menopause 19(9.5) 17(33.3)
Age at Menarche (yr)
Normal menarche (≤16) 136(68.0) 40(78.4)
Delayed menarche (≥17) 64(32.0) 11(21.6)
Age at menopause (yr)
Early menopause (≤45) 38(19.0) 13(25.5)
Normal or late menopause (>46) 162(81.0) 38(74.5)
Gynecological age (yr)
<33 81(40.5) 22(43.1)
≥33 119(59.5) 29(56.9)
Years since menopause (yr)
≤5 43(21.5) 14(27.5)
>5 157(78.5) 37(72.6)
Take an oral contraceptive pill
None use 158(79.0) 34(66.7)
User (Past/Current) 42(21.0) 17(33.3)
Frequency of deliveries
≤3 128(64.0) 43(84.3)
>3 72(36.0) 8(15.7)
Breast feeding
No 13(6.5) 3(5.9)
Yes 187(93.5) 48(94.1)
Age at first pregnant
≤30 193(96.5) 48(94.1)
>30 7(3.5) 3(5.9)
Body Mass Index (kg/m2)
Normal weight or less (<23.0) 68(34.0) 15(29.4)
Over weight (<25.0) 44(22.0) 14(27.5)
Obesity (≥25.0) 88(44.0) 22(43.1)
Abdominal circumference (cm)
Normal 81(40.5) 25(49.0)
Abdominal obesity 119(59.5) 26(51.0)
Waist - Hip ratio (WHR)
Normal 37(18.5) 17(33.3)
Abdominal obesity 163(81.5) 34(66.7)
Hemoglobin (g/dL)
Normal 15(7.5) 4(7.8)
Anemia 185(92.5) 47(92.2)
0.273 0.451
0.021 0.112
0.934 0.622
0.677 0.681
0.064 0.034
0.734 0.461
0.367 0.430
0.005 0.116
0.440 0.478
0.873 0.509
<0.0001 <0.0001
0.148 0.334
0.306 0.366
Variable
N (%) Crude
p  value
Age adjusted
p  value
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5. The frequency analysis according to the time of age at 
menopause 
 
5.1. The time of age at menopause comparison with sociological status and 
health behavior 
Women who had experienced early menopause was less of age-adjusted FMD 
mean 3.3%p (age adjusted p = 0.002), compared to women with normal or late 
menopause. The rate of early menopause was highest in middle-aged (<50) women 
(crude p = 0.008). Women who are married or living together relatively experienced 
normal menopause (crude p = 0.398, age-adjusted p = 0.228). Besides, Education 
levels had positive relation to early menopause (crude p = 0.225, age-adjusted p = 
0.305). There was an inverse correlation between KRS and age at menopause (crude 
p = 0.436), the KRS components such as blood pressure (crude p = 0.364, age-
adjusted p = 0.323), total cholesterol (crude p = 0.336, age-adjusted p = 0.381), 
HDL (crude p = 0.426, age-adjusted p = 0.440), smoking status (crude p = 0.138, 
age-adjusted p = 0.133), and diabetes mellitus (crude p = 0.598, age-adjusted p = 
0.662) was a weak association between time of age at menopause, however there 
was no statistically significance. Lifetime drinking experience was higher in women 
who experienced early menopause (crude p = 0.415, age-adjusted p = 0.480) (Table 
5a). 
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Table 5a. The time of age at menopause comparison with sociological status and health 
behavior
 
Early menopause
Normal or Late
menopause
N 51(20.3) 200(79.7)
4.26 ± 0.94 7.56 ± 0.48 - 0.002
45-49 7(13.7) 5(2.5)
50-59 16(31.4) 83(41.5)
60-69 19(37.3) 76(38.0)
70-88 9(17.7) 36(18.0)
Marrital status
Marriage / Living together 40(78.4) 167(83.5)
Seperation / Divorce / Bereavement 11(21.6) 33(16.5)
Education level
Middle school or less 19(37.3) 101(50.5)
High school or less 27(52.9) 86(43.0)
College or more 5(9.8) 13(6.5)
Diagnosis of CVD  †
None 40(78.4) 168(84.0)
Before menopause 0(0.0) 10(5.0)
After menopause 11(21.6) 22(11.0)
Korean CHD risk scores (KRS)
≤0.01280 32(62.8) 137(68.5)
≤0.13330 ‡ 19(37.3) 63(31.5)
Hypertension (JNCⅦ)
None 16(31.4) 56(28.0)
Pre-hypertension 20(39.2) 96(48.0)
Stage 1 hypertension 9(17.7) 37(18.5)
Stage 2 hypertension 6(11.8) 11(5.5)
<160 2(3.9) 10(5.0)
160-199 12(23.5) 69(34.5)
200-239 22(43.1) 86(43.0)
240-279 12(23.5) 29(14.5)
≥280 3(5.9) 6(3.0)
High density lipoprotein (mg/dL)
<35 0(0.0) 6(3.0)
35-44 9(17.7) 33(16.5)
45-49 5(9.8) 36(18.0)
50-59 20(39.2) 69(34.5)
≥60 17(33.3) 56(28.0)
Smoking
Non-smoker 49(96.1) 198(99.0)
Ever smoker 2(3.9) 2(1.0)
Diabetes mellitus
No 46(90.2) 175(87.5)
Yes 5(9.8) 25(12.5)
Alcohol intake
Non-drinker 30(58.8) 130(65.0)
Drinker (including past drinker) 21(41.2) 70(35.0)
* Age adjusted mean ± SE  † Cardiovascular diseases such as hypertension, myocardial infarction, and angina pectoris ‡ Tertile 3 (≥67%)
Total cholesterol (mg/dL)
0.046 0.021
0.415 0.480
0.426 0.440
0.138 0.133
0.598 0.662
0.336 0.381
Age (yr)
0.008 -
0.398 0.228
0.225 0.305
0.436 -
0.364 0.323
FMD *
Variable
N (%)
Crude
p  value
Age adjusted
p  value
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5.2. The time of age at menopause comparison with Obstetrics & 
gynecological characteristics and anthropometry 
The 20(39.2%) women of those who experienced early menopause as a 
surgical menopause had a significant difference from normal menopause (crude p 
<0.0001, age-adjusted p <0.0001). The age at menarche and menopause were 
positively correlated (crude p = 0.148, age-adjusted p = 0.185), and 98% of women 
experienced early menopause have a gynecological age less than a mean (crude p 
<0.0001, age-adjusted p <0.0001). Most early menopause women had years since 
menopause of more than 5 years (crude p = 0.004, age-adjusted p <0.0001). There 
was no significant relation between oral contraceptive use (crude p = 0.997, age-
adjusted p = 0.943) and the frequency of deliveries (crude p = 0.932, age-adjusted 
p = 0.692). Furthermore, the most women with breastfeeding have normal or later 
of age at menopause (crude p = 0.002, age-adjusted p = 0.003). Women who 
experienced first pregnancy at the old age were relatively fast in age at menopause 
(crude p = 0.115, age-adjusted p = 0.120). 
In a correlation with anthropometry and clinical examination, there was no 
difference in the time of age at menopause according to BMI (crude p = 0.994, age 
adjusted p = 0.983). The waist circumference (crude p = 0.644, age adjusted p = 
0.717), WHR (crude p = 0.696, age adjusted p = 0.864), Hb (crude p = 0.5010, age 
adjusted p = 0.426) were not significantly associated with time of age at menopause. 
(Table 5b) 
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Table 5b. The time of age at menopause comparison with Obstetrics & gynecological 
characteristics and anthropometry 
 
Early menopause
Normal or Late
menopause
N 51(20.3) 200(79.7)
Type of Menopause
Natural menopause 31(60.8) 184(92.0)
Surgical menopause 20(39.2) 16(8.0)
Age at Menarche (yr)
Normal menarche (≤16) 40(78.4) 136(68.0)
Delayed menarche (≥17) 11(21.6) 64(32.0)
Gynecological age (yr)
<33 50(98.0) 53(26.5)
≥33 1(2.0) 147(73.5)
Years since menopause (yr)
≤5 4(7.8) 53(26.5)
>5 47(92.2) 147(73.5)
Duration of HRT usage (months)
None use 38(74.5) 162(81.0)
User (Past/Current) 13(25.5) 38(19.0)
Duration of HRT dosage (months)
None use 38(74.5) 162(81.0)
≤12 5(9.8) 24(12.0)
>12 8(15.7) 14(7.0)
Take an oral contraceptive pill
None use 39(76.5) 153(76.5)
User (Past/Current) 12(23.5) 47(23.5)
Frequency of deliveries
≤3 35(28.6) 136(68.0)
>3 16(31.4) 64(32.0)
Breast feeding
No 8(15.7) 8(4.0)
Yes 43(84.3) 192(96.0)
Age at first pregnant
≤30 47(92.2) 194(97.0)
>30 4(7.8) 6(3.0)
Body Mass Index (kg/m2)
Normal weight or less (<23.0) 17(33.3) 66(33.0)
Over weight (<25.0) 12(23.5) 46(23.0)
Obesity (≥25.0) 22(43.1) 88(44.0)
Abdominal circumference (cm)
Normal 23(45.1) 83(41.5)
Abdominal obesity 28(54.9) 117(58..5)
Waist - Hip ratio (WHR)
Normal 12(23.5) 42(21.0)
Abdominal obesity 39(76.5) 158(79.0)
Hemoglobin (g/dL)
Normal 5(9.8) 14(7.0)
Anemia 46(90.2) 186(93.0)
0.148 0.185
<0.0001 <0.0001
0.145 0.157
0.004 <0.0001
0.306 0.366
<0.0001 <0.0001
Variable
N (%)
Crude
p  value
Age adjusted
p  value
0.997 0.943
0.932 0.692
0.002 0.003
0.696 0.864
0.501 0.426
0.115 0.120
0.994 0.983
0.644 0.717
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6. The multiple linear regression analysis of FMD with HRT  
 
6.1. The linear regression analysis between FMD and HRT usage 
To confirm the correlation of HRT according to the adjusted variable in the 
linear regression analysis, the parameters were sequentially corrected for 5 models. 
The KRS equation is calculated using age, therefore age was excluded from the 
regression model. 
In unadjusted model was a simple relation between FMD and HRT that was 
shown 2.3%p lower in women who experienced HRT (p = 0.031). In the KRS - 
adjusted model, the frequency of FMD in the group with HRT was 2.6%p lower, 
which was stronger (p = 0.015). FMD was 2.1%p lower in the highest KRS group 
(p = 0.021). 
The model 1 adjusted sociological and health behavior. Furthermore, it 
excluded the education levels and moderate physical activity, which were not 
related to previous analysis. The FMD and HRT still had an inversely correlation 
and directionality were similar with the previous model (p = 0.015). Unusually, the 
living alone women have higher FMD compared with married or living together (p 
= 0.029). However, alcohol intake was not significantly associated with FMD (p = 
0.660). 
In a model 2, which was adjusted obstetrics & gynecological history, thereby 
the explanatory power was increased (adjusted R2; 11.5%). HRT was more strongly 
associated with its directionality and FMD was 2.8%p lower in women who 
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experienced HRT (p = 0.012). After adjusted OB & GY history, the effect of KRS 
was weakened (p = 0.077), and the difference in marital status increased (p = 0.010). 
There was no significant correlation between the type of menopause (p = 0.645). 
However, FMD was decreased, women who have an early age at menopause 
(p=0.0005) or a gynecological age (p = 0.005) longer than mean, which is strongly 
related than HRT. Although not statistically significant, the frequency of deliveries 
(p = 0.076), oral contraceptive use (p = 0.664), the first age at pregnancy (p = 0.141) 
and breastfeeding experience (p = 0.991) was showed inverse relation. 
The anthropometry results were adjusted for model 3. HRT was still closely 
related to FMD, after the adjusted various variables (p = 0.006). The effect of 
reduced KRS in model 2 was not statistically related, however, showed a tendency 
to decrease as increasing the risk scores for coronary heart disease. The history of 
OB & GY, which showed inverse relation, tended to weaken while still statistically 
significant. Especially, time of age at menopause (p = 0.0007) and gynecological 
age (p = 0.015) were strongly related. Although not statistically significant, FMD 
was a positive correlation with BMI, and decreasing in higher abdominal obesity 
defined by WHR (p = 0.024) or anemia (p = 0.066).  
The model 4 was adjusted for diagnosis of cardiovascular diseases such as 
hypertension and myocardial infarction before the menopause, there was no 
significant difference in the effect of HRT on FMD (p = 0.702). (Table 6a)
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Table 6a. The multiple linear regression between endothelial function (FMD) and HRT usage 
β p  value β p  value β p  value β p  value β p  value
Model fit
R2 (%) 1.9 4.0 5.8 16.1 19.3
Adjusted R2 (%) 1.5 3.2 4.3 11.5 13.0
Hormone replacement teraphy (HRT)
User (Past/Current) -2.32 0.031 -2.62 0.015 -2.62 0.015 -2.78 0.012 -3.05 0.006
Korean coronary risk scores (KRS)
>0.01280 * -2.13 0.021 -2.70 0.005 -1.80 0.077 -1.77 0.082
Marrital status
Seperation / Divorce / Bereavement 2.55 0.029 3.05 0.010 3.07 0.009
Alcohol intake
Drinker (including past drinker) -0.39 0.660 -0.71 0.424 -1.03 0.251
Type of Menopause
Surgical menopause 0.62 0.645 0.41 0.762
Age at Menarche (yr)
Delayed menarche (≥17) 0.26 0.789 0.18 0.852
Age at menopause (yr)
Early menopause (≤45) -4.87 0.0005 -4.72 0.0007
Gynecological age (yr)
≥33 -3.16 0.005 -2.76 0.015
Years since menopause (yr)
>5 -2.45 0.034 -1.87 0.107
Take an oral contraceptive pill
User (Past/Current) -0.44 0.664 -0.53 0.612
Frequency of deliveries
>3 -1.82 0.076 -1.69 0.105
Breast feeding
Yes -0.02 0.991 -0.21 0.908
Age at first pregnant
>30 -3.23 0.141 -3.11 0.156
Body Mass Index (kg/m2)
Over weight (<25.0) 0.08 0.945
Obesity (≥25.0) 1.12 0.260
Waist - Hip ratio (WHR)
Abdominal obesity -2.47 0.024
Hemoglobin (g/dL)
Anemia -3.03 0.066
Diagnosis of CVD† before menopause
Yes 0.82 0.702
* Tertile 3 (≥67%) † Cardiovascular disease such as hypertension, myocardial infarction
Variable
Unadjusted KRS adjusted
0.0070.031
Model 1 Model 2 Model 3
<0.0001<0.00010.005
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6.2.The linear regression analysis between FMD and duration of HRT 
usage 
The multiple linear regression analysis was performed to determine whether 
there was a change in outcome according to the duration of the hormone treatment. 
All regression analysis models were applied in the same order as the analysis of 
hormone treatment use. 
In the unadjusted model, compared with women who did not receive HRT, 
women who received HRT for one year or less has 1.55%p lower (p = 0.252) and 
women who received HRT greater than 1 year has 3.34%p lower (p = 0.030). 
In the KRS adjusted model, women who have a duration of HRT greater than 
1 year (p = 0.016) were closely related after adjusted for coronary risk scores for 
Korean (p = 0.020). 
In the model 1, the FMD of the separated/divorced / bereavement women (p = 
0.025) was 2.62%p higher than the women who are married and living together, 
and the women who received HRT for more than 12 months (p = 0.012) were 
3.85%p lower than the women who did not receive HRT. The FMD was lower as 
the coronary risk scores for Korean was higher (p = 0.004). 
In the model 2, the FMD in women who had experienced HRT for greater than 
1 year (p = 0.012), who with KRS top 33% (p = 0.070) and who were separated / 
divorced / bereavement (p = 0.008) had a stronger correlation than in previous 
models. The FMD among women who experienced early menopause (p = 0.0006) 
was 4.8%p lower than normal or late menopause women, and 3.18 lower among 
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women who got gynecological age above average (p = 0.005). However, there were 
no significant associations between types of menopause (p = 0.616) and age at 
menarche (p = 0.772). In addition, the women over 5 years since (p = 0.037) 
menopause was 2.42%p lower, on the other hand, no significant relationship was 
found between oral contraceptive use (p = 0.651), frequency of deliveries (p = 
0.072), and the first age at pregnant (p = 0.128). 
In the model 3, there was no significant difference in women who had HRT of 
12 months or less (p = 0.049), however there was a faintly significant association 
in the final model. Women who experienced treatment for more than 1 year (p = 
0.025) were 3.48%p lower and who with the highest KRS top of 33% (p = 0.080) 
and those who were not living together after marriage (p = 0.009) had a significant 
impact of FMD changes. Time of age at menopause (p = 0.0007) and gynecological 
age (p = 0.015) were still significantly associated, and FMD among women who 
are abdominal obesity based on WHR (p = 0.030) was 2.4%p lower than normal 
group. The FMD of women with anemia (p = 0.077) was 2.94%p lower. The years 
since menopause, which showed a significant correlation in the previous model, 
was not statistically significant in this model (p = 0.107). In addition, there were no 
significant associations between FMD and lifetime drinking behavior (p = 0.253), 
type of menopause (p = 0.745), age at menarche (p = 0.843), oral contraceptive use 
(p = 0.609), frequency of deliveries (p = 0.104), breastfeeding (p = 0.899), age at 
first pregnancy (p = 0.150), BMI (p = overweight; p = 0.919, obesity; p = 0.267) 
and diagnosis of CVD before menopause (p = 0.689). (Table 6b)
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Table 6b. The multiple linear regression between endothelial function (FMD) and duration of HRT usage 
β p  value β p  value β p  value β p  value β p  value
Model fit
R2 (%) 2.2 4.3 6.3 16.5 19.3
Adjusted R2 (%) 1.4 3.2 4.4 11.5 12.7
Duration of HRT usage (months)
≤12 -1.55 0.252 -1.80 0.183 -1.70 0.208 -1.97 0.145 -2.72 0.049
>12 -3.34 0.030 -3.71 0.016 -3.85 0.012 -3.89 0.012 -3.48 0.025
Korean coronary risk scores (KRS)
>0.01280 * -2.15 0.020 -2.74 0.004 -1.84 0.070 -1.78 0.080
Marrital status
Seperation / Divorce / Bereavement 2.62 0.025 3.12 0.008 3.11 0.009
Alcohol intake
Drinker (including past drinker) -0.40 0.652 -0.72 0.419 -1.03 0.253
Type of Menopause
Surgical menopause 0.68 0.616 0.44 0.745
Age at Menarche (yr)
Delayed menarche (≥17) 0.28 0.772 0.19 0.843
Age at menopause (yr)
Early menopause (≤45) -4.80 0.0006 -4.69 0.0007
Gynecological age (yr)
≥33 -3.18 0.005 -2.78 0.015
Years since menopause (yr)
>5 -2.42 0.037 -1.88 0.107
Take an oral contraceptive pill
User (Past/Current) -0.46 0.651 -0.54 0.609
Frequency of deliveries
>3 -1.85 0.072 -1.70 0.104
Breast feeding
Yes -0.10 0.957 -0.23 0.899
Age at first pregnant
>30 -3.35 0.128 -3.17 0.150
Body Mass Index (kg/m2)
Over weight (<25.0) 0.12 0.919
Obesity (≥25.0) 1.11 0.267
Waist - Hip ratio (WHR)
Abdominal obesity -2.40 0.030
Hemoglobin (g/dL)
Anemia -2.94 0.077
Diagnosis of CVD† before menopause
Yes 0.86 0.689
* Tertile 3 (≥67%) † Cardiovascular disease such as hypertension, myocardial infarction
0.063 0.012 0.007 <0.0001 <0.0001
Variable
Unadjusted KRS adjusted Model 1 Model 2 Model 3
- 43 - 
 
 
 
 
 
7. The multiple linear regression analysis models with disposing 
of outliers and influences 
 
 
A stepwise variable selection method was used to select statistically 
appropriate variables among the all the independent variables included in multiple 
regression analysis (all the processes are presented in appendix tables). The seven 
individuals were defined as outliers, and 244 individuals were included in the final 
regression model. The explanatory power of regression model without outliers and 
influences are increased slightly than before the disposing, however that were same 
directionality with less effective of overall. 
In the model including the HRT usage (Table 7a), the FMD of the early 
menopause group was 3.92 lower (p = 0.0002), and the abdominal obesity defined 
as WHR was 2.13 lower (p = 0.012). Women who has gynecological age more than 
average (≥33yr) was 3.02 lower (p = 0.0006). The women take a HRT were 1.75 
lower (p = 0.040). Furthermore, the greater than 5 years since menopause group 
was 1.65 lower (p = 0.059). Women with the highest 33% risk for KRS was 2.21 
lower of FMD (p = 0.005). On the other hand, in marriage status with only positive 
correlation, the FMD of the separated/divorced / bereavement women was 
significantly 2.34 higher than the women who marriage and living together (p = 
0.011). 
In other models including the duration of HRT usage (Table 7b), the FMD was 
3.95 lower in early age at menopause group (p = 0.0002), 2.20 lower in abdominal 
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obesity group (p = 0.011) and 2.99 lower in gynecological age over 33 years (p = 
0.0007). The years since menopause greater than 5 years was 1.64 lower (p = 0.060) 
and 2.18 lower in the highest KRS group (p = 0.005). The women who experience 
separation / divorce / bereavement was 2.32%p higher at (p = 0.012). However, in 
the duration of HRT usage, an inverse correlation between HRT, the FMD was 2.07 
lower in short-term users (less than 12 months; p = 0.054) and 1.31 lower in long-
term users (greater than 12months; p = 0.285), there was no statistically significant 
at the 5% significance level. 
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Table 7a. The final regression analysis without outliers and influences 
(HRT usage) 
Table 7b. The final regression analysis without outliers and influences 
(duration of HRT usage) 
β p  value β p  value
N
Outliers & influences
Model fit
R2 (%) 16.1 16.6
Adjusted R2 (%) 13.7 14.2
Age at menopause (yr)
Early menopause (≤45) -4.91 0.0001 -3.92 0.0002
Waist - Hip ratio (WHR)
Abdominal obesity -2.59 0.012 -2.13 0.012
Gynecological age (yr)
≥33 -3.06 0.004 -3.02 0.0006
Hormone replacement teraphy (HRT)
User (Past/Current) -2.77 0.007 -1.75 0.040
Years since menopause (yr)
>5 -2.05 0.0001 -1.65 0.059
Korean coronary risk scores (KRS)
>0.01280 * -2.07 0.029 -2.21 0.005
Marrital status
Seperation / Divorce / Bereavement 2.43 0.030 2.34 0.011
* Tertile 3 (≥67%)  † Reweighted
<0.0001 <0.0001
7 †
Variable
Step 1
251 251
β p  value β p  value
N
Outliers & influences
Model fit
R2 (%) 16.2 16.7
Adjusted R2 (%) 13.4 13.9
Age at menopause (yr)
Early menopause (≤45) -4.87 0.0001 -3.95 0.0002
Waist - Hip ratio (WHR)
Abdominal obesity -2.51 0.017 -2.20 0.011
Gynecological age (yr)
≥33 -3.09 0.004 -2.99 0.0007
Duration of HRT usage (months)
≤12 -2.35 0.072 -2.07 0.054
>12 -3.30 0.024 -1.31 0.285
Years since menopause (yr)
>5 -2.05 0.053 -1.64 0.060
Korean coronary risk scores (KRS)
>0.01280 * -2.11 0.027 -2.18 0.005
Marrital status
Seperation / Divorce / Bereavement 2.45 0.028 2.32 0.012
* Tertile 3 (≥67%)  † Reweighted
7 †
<0.0001 <0.0001
Variable
Step 1
251 251
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Ⅳ. DISCUSSION AND CONCLUSION 
 
 
The aim of this study is to confirm the relationship between several 
postmenopausal characteristics and endothelial function after adjusted coronary 
risk scores for Korean. Vascular endothelial dysfunction affects cardiac function 
(Maruhashi et al., 2013), and heart disease is the leading cause of death in Korean 
women. Menopause, an inevitable physical change in women, is known to 
increased risk for related diseases due to metabolic degradation such as 
hyperlipidemia, abdominal obesity, hot flushes, bone loss and inflammatory 
changes, etc. (Li et al., 2012; Stefanick, 2010).   
The estrogen has a positive effect on lipid metabolism, it lowers LDL and 
increases HDL, thereby increasing vascular nitrogen oxides (NO) and reducing the 
risk of cardiovascular disease (Best et al., 1998). In other studies, however, 
postmenopausal women’s estradiol (E2) concentration had a significant relation to 
myocardial fat in the low-estradiol group and increased CVD-related risk, 
depending on the type of estrogen, even though secreted estrone (E1) from women’s 
body fat (El Khoudary et al., 2017). Nevertheless, there is no definitive prophylactic 
hormone replacement treatment for the increased risk of vascular disease in 
postmenopausal women.  
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The most representative type of HRT, a single regimen method: only 
administers estrogen regimen, and a combination method: uses estrogen plus 
progestin. Postmenopausal HRT for the first-line prevention of women tends to 
reduce the risk of CHD, Moreover, the blood estrogen levels have a protective effect 
against cardiovascular disease (Farhat, Lavigne and Ramwell, 1996). As is known, 
a single dose of estrogen effects to cardioprotective, however, the combined use of 
estrogen plus progestin increases the risk of cardiovascular disease, breast cancer. 
Besides, both of treatment method were increase of risk of veno-thrombotic 
episodes, stroke and cholecystitis (FALKEBORN et al., 1992; Grodstein  et al., 
1996; Investigators, 2002; Koo, Song and Na, 2012; Manson et al., 2003; Miller et 
al., 1995; Rossouw et al., 2007). When the women receive naïve HRT, who may 
experience side effects such as vaginal bleeding, mood changes, and indigestion 
during short-term. In some cases, the symptoms are considered to change 
medication prescription. Continuous therapy has prophylactic effects on 
osteoporosis and coronary artery disease. On the other hand, HRT may not be 
recommended for all postmenopausal women because of the increased risk of breast 
cancer, endometrial cancer, gallbladder disease, stroke and fracture in long-term 
usage.  
In this study, individuals who postmenopausal women have 62 years mean of 
age.  Older group (age over 70) are 18% of the total, there was no significant 
difference in FMD mean by age, the FMD of married women with 
separated/divorced/ bereavement (mean age; 68.6 years) was significantly higher 
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than women who live together after marriage (60.8 years). In addition, mean of 
gynecological age was lower (31.8 years) compared with women who living 
together after the marriage (33.2 years), and there was no significant difference in 
postmenopausal age. However, women who living alone experienced (mean; 21.2 
years) many years since of menopause compared with women who live together 
(12.2 years). Thus, it was found that marital status of women was independently 
related to after the menstrual characteristics. It is anticipated the stress from a 
patriarchal culture which is a characteristic of the Korean society in the past, in fact, 
because most of the individuals are elderly who has a mind of women’s 
responsibility in the house such as housework. Rather, the decrease in endothelial 
function was greater immediately after menopause. that suggest the years since 
menopause was strongly related with endothelial function. 
The difference in the risk scores for coronary artery disease for Korean (KRS) 
according to the time of age at menopause was significantly higher in the late 
menopause women than the early or normal menopause group. The mean age of the 
nine late menopause women was 65.9 years, which was older than early menopause 
(61.4 years) and normal menopause women (62.2 years). KRS was significantly 
lower in the women experienced HRT compared with non-experienced HRT. The 
median difference of endothelial function, by the age group, was higher during 
menopause in each group, then gradually decreased after the menopause. There was 
no significant difference, by the HRT usage, whereas the lower in HRT usage 
women. These results suggest HRT is associated with the prevention of coronary 
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risk scores. The endothelial dysfunction which independent association with the 
occurrence of coronary artery disease (Sader and Celermajer, 2002) had an inverse 
relation with KRS after the adjusted with menstrual characteristics variables 
suggest that has a strong association within. 
Unlike the previous results, when adjusted for endothelial function and the 
variables affecting women’s health, FMD was significantly lower in the women 
who experienced HRT than non-use group. Because this study designed a cross-
sectional study using cohort data, it is unclear of timing at HRT is initiated. 
Therefore, if HRT is initiated after the onset of deterioration of endothelial function 
due to aging or other causes, furthermore, the reverse causation can occur in rural 
women who are less likely to be prescribed HRT for the prevention of disease. 
Nevertheless, when further analysis of the duration of HRT was undertaken, FMD 
was lower in women who underwent HRT within 12 months compared with those 
who used HRT over 12 months. The mean age of women who received HRT usage 
during short-term (≤12 months) was 58.8 years, those who were younger than HRT 
non-users (62.9 years) and long-term users (>12 months, 60.1 years). The mean of 
years since menopause was 11.3 years was shorter than the other groups (non-users; 
14 years, long-term users; 14.5 years). The women with short-term used of HRT 
have recently been menopause. That suggest FMD is lowered the Immediately 
afterward of menopause than after many years since menopause. 
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Among the FMD was 3.3%p lower in the early menopause group, that suggest 
the decrease endothelial function of women whose hormone decreasing started at a 
relatively early age is weaker. In order to confirm the accuracy, we calculated the 
gynecological age (duration between from age at menarche to age at menopause) 
and included in the analysis, In the Korean Heart Study (KHS) which is large-scale 
population study, the shorter the hormone exposure period, the risk of 
cardiovascular disease was increased (Jung et al., 2016). However, we found 
women who has a longer gynecological age (≥33 years) has significantly decreased 
in endothelial function. In fact, although gynecological age is not long in all late 
menopause women, in this study, only one woman had a long gynecological age in 
early menopause (mean; 28.2 years). Most of the normal or late menopause group 
has an average or more of gynecological age. The women who were shorter than 33 
years of gynecological age had a relatively length years since menopause (mean; 
19.3 years), which was longer than who has longer gynecological age (9.9 years). 
These findings suggest when the estradiol concentration goes lowering in the 
menopausal woman’s body, the endothelial function is sharply lowered. 
The endothelium-dependent function is an inverse relation with weight (Arkin 
et al., 2008). The previous study suggests the WHR, among a healthy overweight 
woman, is a closely independent predict factors for endothelial function (Brook et 
al., 2001). In this study, no mean difference of FMD between abdominal obesity 
defines as a waist circumference only, however, the abdominal obesity women 
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based on WHR is a significant correlation with endothelial function. Abdominal 
obesity is a risk factor for various metabolic diseases. This result suggests there is 
a strong correlation between endothelial function and abdominal obesity, which is 
not simply based on waist circumference, but the excess accumulation of fat in the 
abdomen compared to a balanced body. In contrast to previous results, abdominal 
obesity group (mean age; 63 years) was older than normal group (56.5 years). 
Obviously, the postmenopausal period was shorter in the normal group (median; 8 
years) than in the abdominal obesity group (14 years). Nevertheless, decreased 
endothelial function in the abdominal obesity group is because obesity itself affects 
weakens of vessel function (Stapleton et al., 2008). 
Postmenopausal women experience loss of estradiol in the body, moreover 
decreased the function of related receptors affect the dysfunction of endothelial 
cells, as a result in decreased metabolic function and increased risk of vascular 
disease (Li et al., 1999). Previous studies have shown estrogen elevation via HRT 
reduces cell transition by aging through estrogen receptors and contributes to nitric 
oxide (NO) release, thereby improving endothelial function (Hayashi et al., 1995; 
Khalil, 2013; Li et al., 1999). In contrast, in older postmenopausal women should 
be considered in prescribing because the effects of aging are stronger than the 
prophylactic effects of HRT (Compston, 1997). 
We could confirm the association endothelium-dependent function with 
various menstrual characteristics in postmenopausal women living in Korea rural 
areas. As a result, women who has a gynecological age was over 33 years, the years 
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since menopause more than 5 years, the upper 33% of KRS, the abdominal obesity 
by WHR, women who are living together after the marriage had 13%p lower on 
endothelial function. In this study, older postmenopausal women who experienced 
HRT usage and early age at menopause have a negative effect on postmenopausal 
endothelium-dependent function. In addition, years since menopause, must be 
considered when deciding to initiate HRT. The longer of period, the weakens of 
hormone receptor and the prophylactic effect of HRT cannot be expected. That 
suggest the backup previous hypothesis, in older, postmenopausal women may 
increase risk rather than preventive effects.  
From another perspective, HRT is more likely to be recommended because 
women with severe menopause symptoms or poor of health condition, that may 
visit the hospital frequently. Besides, women with cardiovascular risk factors may 
growth plaques of vascular wall and increased risk of myocardial infarction after 
the HRT (Medina et al., 2003). In some, women who started HRT early after the 
menopause, risk of mortality, heart failure and myocardial infarction was reduced 
without an increased risk of stroke, some of cancer, and venous thromboembolism 
when HRT usage (Schierbeck et al., 2012). 
Nevertheless, there are many side effects and benefits in HRT, and since there 
are still no clear guidelines, prior to exogenous HRT, postmenopausal women need 
to increase the intake of foods rich in phytoestrogen, such as soy, fruits and improve 
their lifestyles to prevent chronic diseases caused by hormone decrease and 
metabolic degradation. The timing of HRT initiation should be based on family 
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history, individual health status, cardiovascular risk factors such coronary risk 
scores (KRS). Furthermore, duration of HRT usage should be decided accordingly. 
We anticipate that the relatively inhabitants of rural areas in the elderly will lack 
knowledge which preventive treatment due to information asymmetry. In Korea, 
rural area where women’s chronic diseases and deaths from heart disease are 
increasing, the municipality should be developed programs and implemented to 
prevent diseases through related women’s health education. This is could be a 
policy to reduce the sociological cost of the disease. 
The limitation of this study was designed cross-sectional, thus, the timing of 
postmenopausal HRT is unclear in this data. Moreover, to examine the individuals 
were specific women living in rural area (Yangpyeong, Gyeonggi) in Korea. There 
was not enough randomized assignment in the selection process. Besides, that may 
have an error in performing an endothelium-dependent vasodilation test that is 
sensitive to the measurement environment and the skill of the tester. More 
prospective studies will need to be undertaken to investigate the history of HRT 
such as the timing of HRT initiation, regimen, and dosage, etc., and the broader area 
not only rural area. 
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APPENDIX 
 
Table A1. Process of selection independent variables by stepwise method for linear regression equation (HRT usage) 
 
 
β p  value β p  value β p  value β p  value β p  value β p  value β p  value
Model fit
R2 (%) 3.6 6.9 9.3 11.5 13.3 14.4 16.1
Adjusted R2 (%) 3.2 6.2 8.2 10.0 11.6 12.3 13.7
Age at menopause (yr)
Early menopause (≤45) -3.21 0.003 -3.29 0.002 -5.17 <0.0001 -4.96 0.0001 -4.86 0.0001 -5.03 <0.0001 -4.91 0.0001
Waist - Hip ratio (WHR)
Abdominal obesity -3.07 0.003 -2.94 0.004 -3.30 0.001 -2.79 0.007 -2.55 0.014 -2.59 0.012
Gynecological age (yr)
≥33 -2.63 0.012 -2.56 0.014 -3.06 0.004 -3.34 0.002 -3.06 0.004
Hormone replacement teraphy (HRT)
User (Past/Current) -2.56 0.014 -2.64 0.011 -2.81 0.007 -2.77 0.007
Years since menopause (yr)
>5 -2.37 0.023 -1.93 0.069 -2.05 0.053
Korean coronary risk scores (KRS)
>0.01280 * -1.65 0.077 -2.07 0.029
Marrital status
Seperation / Divorce / Bereavement 2.43 0.030
* Tertile 3 (≥67%)
<0.00010.003 0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Step 7Step 6
Variable
Step 1 Step 2 Step 3 Step 4 Step 5
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Table A2. Process of selection independent variables by stepwise method for linear regression equation (duration of HRT usage) 
β p  value β p  value β p  value β p  value β p  value β p  value β p  value
Model fit
R2 (%) 3.6 6.9 9.3 11.0 12.2 13.6 16.2
Adjusted R2 (%) 3.2 6.2 8.2 9.5 10.4 11.4 13.4
Age at menopause (yr)
Early menopause (≤45) -3.21 0.003 -3.29 0.002 -5.17 <0.0001 -5.08 <0.0001 -4.94 0.0001 -5.11 <0.0001 -4.87 0.0001
Waist - Hip ratio (WHR)
Abdominal obesity -3.07 0.003 -2.94 0.004 -2.44 0.019 -2.53 0.015 -2.26 0.029 -2.51 0.017
Gynecological age (yr)
≥33 -2.63 0.012 -3.10 0.004 -2.82 0.009 -3.07 0.004 -3.09 0.004
Years since menopause (yr)
>5 -2.27 0.031 -2.47 0.019 -2.01 0.060 -2.05 0.053
Marrital status
Seperation / Divorce / Bereavement 2.03 0.067 2.49 0.028 2.45 0.028
Korean coronary risk scores (KRS)
>0.01280 * -1.86 0.052 -2.11 0.027
Duration of HRT usage (months)
≤12 -2.35 0.072
>12 -3.30 0.024
* Tertile 3 (≥67%)
Variable
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7
0.003 0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
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ABSTRACT (IN KOREAN)  
 
한국 농촌지역 여성의 폐경 후 호르몬대체요법과 
조기 폐경이 내피세포기능에 미치는 영향 
최윤수 
연세대학교 보건대학원 
지도교수 지선하 
연구배경 및 목적 
심혈관질환은 국내 성인 사망원인 2 위이다. 여성의 폐경은 심혈관 질환의 
위험인자로 알려져 있으며, 내피 세포 기능 장애는 관상 동맥 질환의 
독립적인 위험인자이다. 폐경 후 호르몬대체요법에는 많은 부작용과 이점이 
있지만 심혈관 질환에 대해서는 여전히 많은 논란이 있다. 본 연구에서는 
관상 동맥 질환 위험도 등을 보정한 후 폐경 시기와 호르몬 대체요법이 
내피세포 기능에 미치는 영향을 알아보고자 한다. 
 
연구방법 
경기도 양평 지역에서 시행된 장수 코호트 자료에서 FMD 검사를 받고 
설문조사에 결측이 없는 251 명의 여성을 대상으로 하였다. 최종 
회귀분석에서 이상치 처리를 위해 가중치 재부여 방법을 사용하였다. 
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연구결과 
호르몬 재배치 치료를 받은 51 명(20.3%)의 여성의 내피 기능은 1.75%p 
(p=0.04)낮았고, 조기 폐경을 경험한 여성 51 명(20.3%)은 3.92%p 
(p=0.0002) 낮았다. 호르몬 치료를 경험하지 않은 여성에 비해 단기간 
호르몬 치료를 경험한 여성은 2.07%p(p=0.054), 장기간 호르몬 치료를 
경험한 여성은 1.31%p(p=0.285) 낮았다. WHR 로 정의된 복부비만 
(p=0.012)이거나, 월경 기간(초경부터 폐경까지의 기간)이 평균 이상 
(p=0.0006)이면서, KRS 가 높고(p=0.005) 폐경 후 기간이 긴(p=0.059) 
여성은 내피 기능이 감소했다. 대조적으로, 독거 중인 폐경 후 노인 여성은 
결혼 후 동거중인 여성에 비해 내피세포 기능이 유의하게 높았다(p=0.012). 
 
결론 
호르몬 재배치 치료를 시작할 때, 현재 나이와 폐경의 종류만이 아니라 관상 
동맥 질환 위험 점수, 월경 기간 등을 모두 고려해야한다. 
 
핵심 단어:  
폐경, 호르몬대체요법, 내피세포기능, 심혈관 질환, 조기 폐경, 월경 
기간 
